AstraZeneca Hits U.K. Antitrust Review with $39B Alexion Buy After U.S. FTC Clearance
May 25, 2021
By: Angus Liu
FiercePharma
Axinn partner Jeny Maier’s commentary was included in the FiercePharma article, "AstraZeneca Hits U.K. Antitrust Review with $39B Alexion Buy After U.S. FTC Clearance."
Click here to access the article.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
IBA Annual Conference 2025
Speaking Engagement
Antitrust
Thomson Reuters 24th Annual Law Firm COO & CFO Forum
Speaking Engagement
LegalNEXT 2025
Speaking Engagement
Antitrust
Informa Antitrust Texas 2025
Speaking Engagement
Antitrust
ACI Forum on Pharma & Biotech Patent Litigation USA 2025
Speaking Engagement
Intellectual Property
MCCA Gala 2025
Sponsorship
Antitrust
Antitrust 101: Trial-Minded Antitrust Discovery
Webinar
Antitrust
ABA Antitrust Plaintiffs' Roundtable 2025
Speaking Engagement
Antitrust
Centerforce IP Strategy Summit: Palo Alto
Speaking Engagement
Intellectual Property
Corporate Counsel Women, Influence, & Power in Law Conference 2025
Speaking Engagement
Antitrust